Vista Pharmaceuticals (BOM:524711) Moat Score: 0/10 (As of Aug. 01, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:524711 Vista Pharmaceuticals Ltd BOM:524711
51 GF Score
Price ₹6.50
GF Value ₹6.11
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Vista Pharmaceuticals Moat Score?

Vista Pharmaceuticals has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

Vista Pharmaceuticals has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Vista Pharmaceuticals might have No Moat - No discernible moat.

Vista Pharmaceuticals  (BOM:524711) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Vista Pharmaceuticals Moat Score Related Terms

BOM:524711
51GF Score
Vista Pharmaceuticals Ltd BOM:524711
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Vista Pharmaceuticals (BOM:524711) Overvalued in 2026?

Based on GuruFocus' analysis, Vista Pharmaceuticals stock appears to be overvalued. The current stock price of ₹6.50 is trading 6.4% above its estimated GF Value™ of ₹6.11. GuruFocus considers Vista Pharmaceuticals to be Fairly Valued.

Key valuation signals for BOM:524711:

  • Moat Score: 0
  • GF Value™: ₹6.11 vs. price of ₹6.50 (6.4% above fair value)
  • GF Score™: 51/100 with 4 warning signs

No single metric tells the full story. See the BOM:524711 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vista Pharmaceuticals Business Description

Address Kakateeya Hills, Plot No. 104, Ravindra Co Operative Society, Guttala Begumpet, Hyderabad, TG, IND, 500033
Vista Pharmaceuticals Ltd is an Indian company engaged in a single operating segment, which is the manufacturing of Pharmaceutical products. The company offers over-the-counter and prescription generic drug products such as tablets, capsules, and liquids covering various therapeutic categories. Some of the drugs in tablet dosage forms are Sulfamethoxazole and Trimethoprim, Bismuth Subgallate, Pyrantel Pamoate, Aspirin, Ibuprofen, Ranitidine HCl, and others. Nifedipine, Piroxicam, and Indomethacin are the drugs offered by the company in a capsule dosage form. The company generates all of its operating revenue from sales within its domestic market.
51GF Score

Get the complete analysis for BOM:524711

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹6.50
Price
₹6.11
GF Value